- Home
- PEGA vs LEGN Comparison
PEGA vs LEGN Comparison
Compare PEGA & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEGA
- LEGN
- Stock Information
- Founded
- PEGA 1983
- LEGN 2014
- Country
- PEGA United States
- LEGN United States
- Employees
- PEGA N/A
- LEGN N/A
- Industry
- PEGA EDP Services
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- PEGA Technology
- LEGN Health Care
- Exchange
- PEGA Nasdaq
- LEGN Nasdaq
- Market Cap
- PEGA 7.8B
- LEGN 7.0B
- IPO Year
- PEGA 1996
- LEGN 2020
- Fundamental
- Price
- PEGA $93.07
- LEGN $31.78
- Analyst Decision
- PEGA Buy
- LEGN Strong Buy
- Analyst Count
- PEGA 13
- LEGN 13
- Target Price
- PEGA $100.38
- LEGN $79.42
- AVG Volume (30 Days)
- PEGA 1.0M
- LEGN 1.5M
- Earning Date
- PEGA 04-22-2025
- LEGN 05-13-2025
- Dividend Yield
- PEGA 0.13%
- LEGN N/A
- EPS Growth
- PEGA 156.48
- LEGN N/A
- EPS
- PEGA 2.14
- LEGN N/A
- Revenue
- PEGA $1,642,666,000.00
- LEGN $627,241,000.00
- Revenue This Year
- PEGA $9.61
- LEGN $65.96
- Revenue Next Year
- PEGA $6.09
- LEGN $52.55
- P/E Ratio
- PEGA $43.53
- LEGN N/A
- Revenue Growth
- PEGA 14.29
- LEGN 119.97
- 52 Week Low
- PEGA $55.71
- LEGN $29.27
- 52 Week High
- PEGA $113.67
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- PEGA 69.13
- LEGN 41.49
- Support Level
- PEGA $90.82
- LEGN $30.25
- Resistance Level
- PEGA $95.67
- LEGN $35.81
- Average True Range (ATR)
- PEGA 2.87
- LEGN 1.45
- MACD
- PEGA 0.82
- LEGN -0.18
- Stochastic Oscillator
- PEGA 90.89
- LEGN 27.58
About PEGA Pegasystems Inc.
Founded in 1983, Pegasystems provides a suite of solutions for customer engagement and business process management. The company's key offering is the Pega Infinity platform, which combines business process management with customer relationship management applications. The company focuses on enterprise-size customers in the financial, insurance, and healthcare industries.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.